

Company Registration No. 02658906 (England and Wales)

ASPAR PHARMACEUTICALS LIMITED
DIRECTORS' REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2023

THURSDAY



ACYV84Y

A06

14/03/2024

#71

COMPANIES HOUSE

ASPAR PHARMACEUTICALS LIMITED

COMPANY INFORMATION

Directors

T.E. Prudhoe
Mrs S.J. Prudhoe
J.E. Prudhoe

Secretary

J.E. Prudhoe

Company Number

02658906

Registered office

Albany House
Acrewood Way
St Albans
Hertfordshire
AL4 0YJ

Auditors

David Morgan & Co Limited
8 Peterborough Road
Harrow
HA1 2BQ

Business address

Albany House
Acrewood Way
St Albans
Hertfordshire
AL4 0YJ

ASPAR PHARMACEUTICALS LIMITED

CONTENTS

	Page
Strategic report	1
Directors' report	2 - 3
Independent auditors' report	4 - 6
Profit and loss account	7
Balance sheet	8
Statement of changes in equity	9
Cash flow statement	10
Notes to cash flow statement	11
Notes to the financial statements	12 - 21

ASPAR PHARMACEUTICALS LIMITED

STRATEGIC REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2023

The directors present their strategic report on the company for the year ended 30 September 2023.

Review of the business

The principal activity of the company continued to be that of the manufacturing, packaging and distribution of pharmaceutical products to the wholesale and retail markets within the UK.

Turnover during the year ended 30 September 2023 increased from 14M in 2022 to 15.7M in 2023, a rise of 12% year on year. This was primarily driven by ongoing strong sales demand within the OTC analgesics market.

As with many businesses of our size, the business environment in which we operate continues to be challenging. The OTC analgesic market in the UK is highly competitive and regulated and competition from both within and without the UK is strong. With these risks and uncertainties in mind we are aware that any plans for future development of the business maybe subject to unforeseen events outside of our control. The company is increasingly liquid in its resources and assets. A significant number of customers are FTSE companies and payment terms are generally met on time. Debtor days have fallen year on year primarily due to a bad debt from Wilkinsons Retailer which went into liquidation in 2023. However, the profit after tax declared in 2023 represents a return on turnover of 12.7% up from 9% in 2022 and despite this set back is reflected in healthy bank balances at the year end. Liquidity rates have increased from 4.02 to 4.42 over the course of the financial year. The company is highly regulated by the MHRA and constant vigilance is required to ensure that the company's quality control is fully compliant and adaptable to changing regulatory environments. Competition both domestically and from abroad is always a factor in determining price as is sourcing its supply of raw materials and ensuring that the company's plant and equipment is kept up to date and functioning efficiently thereby assuring the output of the finished product is kept to a high regulatory standard.

The company's positive results has enabled it to maintain a very strong balance sheet position at the year end with net assets of £16.2M (2022 - £14.2M). The company continues to invest in new plant and machinery for the factory and the directors are confident that margins and turnover can be maintained and grow in future years.

We consider our key financial performance indicators are those that communicate the financial performance of the company as a whole, these being turnover, gross profit, net operating profit before tax and return on capital employed. The turnover of the company rose to £15.7M in 2023 from £14M in 2022, an increase of 12%. The company's gross margins also rose marginally from 53% in 2022 to 56% in 2023, mostly as a result of increasing sales prices. Net profit before tax increased to £2.6M in 2023 from £1.6M in 2022, an increase of 67%. The return on capital employed has risen in line with the increase in profits from 8.9% in 2022 to 12.4% in 2023.

By order of the board



T.E. Prudhoe
Director
12 March 2024

ASPAR PHARMACEUTICALS LIMITED

DIRECTORS' REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2023

The directors present their report and financial statements for the year ended 30 September 2023.

Future developments

The disclosure of future developments is set out in the Strategic Report on Page 1.

Results and dividends

The results are set out on page 7.

Directors

The following directors have held office since 1 October 2022:

T.E. Prudhoe
Mrs S.J. Prudhoe
J.E. Prudhoe

Disabled persons

The company's policy is to recruit disabled workers for those vacancies that they are able to fill. All necessary assistance with initial training courses is given. Once employed, a career plan is developed so as to ensure suitable opportunities for each disabled person. Arrangements are made, wherever possible, for retraining employees who become disabled, to enable them to perform work identified as appropriate to their aptitudes and abilities.

Auditors

David Morgan & Co Limited were appointed auditors to the company and in accordance with section 485 of the Companies Act 2006, a resolution proposing that they be re-appointed will be put at a General Meeting.

ASPAR PHARMACEUTICALS LIMITED

DIRECTORS' REPORT (CONTINUED) **FOR THE YEAR ENDED 30 SEPTEMBER 2023**

Directors' responsibilities

The directors are responsible for preparing the Strategic Report and the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have prepared the financial statements in accordance with United Kingdom Accounting Standards, comprising FRS 102 "The Financial Reporting Standard applicable in the UK and ROI", and applicable law (United Kingdom Generally accepted Accounting Practice).

Under company law the directors must not approve the financial statements unless they are satisfied they give a true and fair view of the state of affairs of the company and of the profit and loss of the company in that period. In preparing these financial statements, the directors are required to:

select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable accounting standards, including FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements;
notify its shareholders in writing about the use of disclosure exemptions, if any, of FRS 102 used in the preparation of financial statements; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation into the jurisdictions.


Statement of disclosure to auditors

The directors at the date of approval of the report each confirm that:

So far as the directors are aware, there is no relevant audit information of which the company's auditors are unaware. Additionally, the directors have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company's auditors are aware of that information.

On behalf of the board

T.E. Prudhoe
Director
12 March 2024



ASPAR PHARMACEUTICALS LIMITED

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF ASPAR PHARMACEUTICALS LIMITED

Report on the financial statements

We have audited the financial statements of Aspar Pharmaceuticals Limited for the year ended 30 September 2023 which comprise the statutory profit and loss, balance sheet, cash flow and statement of changes in equity and notes to the financial statements, including a summary of the significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and UK Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and ROI.

In our opinion the financial statements:

- Give a true and fair view of the state of the company's affairs as at 30 September 2023 and of its profit for the year then ended
- have been properly prepared in accordance with UK GAAP and;
- have been prepared in accordance with the Companies Act 2006.

Basis for Opinion

We conducted our audit in accordance with International Standards on auditing (UK) (ISAs UK) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusion relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of the report.

Other information

The directors are responsible for the other information. The other information comprises the information included in the Strategic Report and Directors' Report, other than in the financial statements and our auditors report thereon.

ASPAR PHARMACEUTICALS LIMITED

INDEPENDENT AUDITORS' REPORT (CONTINUED) TO THE MEMBERS OF ASPAR PHARMACEUTICALS LIMITED

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the Strategic Report and the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and the Strategic Report and the Directors' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic and Directors' Report.

We have nothing to report in respect of the following matters in relation to which the Companies act 2006 requires us to report to you if, in our opinion:

adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
The directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemptions in preparing the Directors' Report and from the requirement to prepare a Strategic Report.

Responsibilities for the financial statements and the audit

As explained more fully in the Directors' Responsibilities Statement set out in pages 2 - 3, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative to do so.

ASPAR PHARMACEUTICALS LIMITED

INDEPENDENT AUDITORS' REPORT (CONTINUED) TO THE MEMBERS OF ASPAR PHARMACEUTICALS LIMITED


Auditors responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurances about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but it is not a guarantee that an audit is conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can be expected to influence the economic decisions of users on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the financial Reporting Councils website at: [https:// www.frc.org.uk/Our-Work/Audit/Audit-and-assurance/Standards-and-guidance/Standards-and-guidance-for-auditors/Auditors-responsibilities-for-audit/description-of-auditors-responsibilities-for-audit.aspx](https://www.frc.org.uk/Our-Work/Audit/Audit-and-assurance/Standards-and-guidance/Standards-and-guidance-for-auditors/Auditors-responsibilities-for-audit/description-of-auditors-responsibilities-for-audit.aspx). This description forms part of our audit report.

Use of our Report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinion we have formed.



.....
Simon Byrne (Senior Statutory Auditor)
for and on behalf of David Morgan & Co Limited
Chartered Accountants
Statutory Auditor

12 March 2024

ASPAR PHARMACEUTICALS LIMITED

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 30 SEPTEMBER 2023

	Notes	2023 £	2022 £
Turnover	3	15,718,946	14,035,660
Cost of sales		(6,806,191)	(6,671,527)
Gross Profit		8,912,755	7,364,133
Administrative expenses		(6,316,512)	(5,751,968)
		2,596,243	1,612,165
Other operating income		3,024	1,946
Operating profit	4	2,599,267	1,614,111
Other interest receivable and similar income	5	-	778
Interest payable and similar charges	6	-	54,164
		2,599,267	1,560,725
Taxation	7	(604,936)	(292,963)
		1,994,331	1,267,762

ASPAR PHARMACEUTICALS LIMITED

BALANCE SHEET AS AT 30 SEPTEMBER 2023


	Notes	2023 £	2022 £
Fixed assets			
Tangible assets	8	8,434,567	9,022,094
Current assets			
Inventories	9	3,095,380	2,888,005
Debtors	10	2,310,324	2,950,393
Cash at bank and in hand		4,566,197	1,053,486
		<u>9,971,901</u>	<u>6,891,884</u>
Creditors: amounts falling due within one year	11	<u>(2,254,047)</u>	<u>(1,719,725)</u>
Net current assets		<u>7,717,854</u>	<u>5,172,159</u>
Total assets less current liabilities		16,152,421	14,194,253
Provisions for liabilities	12	30,303	(5,861)
		<u>16,182,724</u>	<u>14,188,392</u>
Capital and reserves			
Called up share capital	14	45,100	45,100
Profit and loss account		16,137,624	14,143,293
Shareholders funds		<u>16,182,724</u>	<u>14,188,393</u>

Approved by the board and authorised for issue on 12 March 2024

T.E Prudhoe
Director



J.E. Prudhoe
Director



Company Registration No. 2658906

ASPAR PHARMACEUTICALS LIMITED

STATEMENT OF EQUITY

FOR THE YEAR ENDED 30 SEPTEMBER 2023

	Called-up Share Capital	Retained Earnings	Total Equity
Balance as at 1 October 2021	45,100	12,875,531	12,920,631
Profit for the financial year		1,267,762	1,267,762
Balance as at 30 September 2022 and 1 October 2022	45,100	14,143,293	14,188,393
Profit for the financial year		1,994,331	1,994,331
Balance as at 30 September 2023	45,100	16,137,624	16,182,724

ASPAR PHARMACEUTICALS LIMITED

CASH FLOW STATEMENT FOR THE YEAR ENDED 30 SEPTEMBER 2023

	2023 £	2022 £
Cash flow from operating activities	4,089,403	1,293,612
Interest paid	-	(54,164)
Taxation	(304,213)	(551,000)
Dividends received	-	778
Net cash flow from operating activities	<u>3,785,190</u>	<u>689,226</u>
Cash flow from investing activities		
Payments to acquire tangible assets	(272,479)	(368,172)
Receipts from sales of tangible assets	-	65,000
Net cash flow from investing activities	<u>(272,479)</u>	<u>(303,172)</u>
Cash flow from financing activities		
Repayment of long term bank loan	-	(777,716)
Net cash flow from financing activities	<u>-</u>	<u>(777,716)</u>
(Decrease)/increase in cash in year	3,512,711	(391,662)
Cash and cash equivalents at beginning of year	1,053,486	1,445,148
Cash and cash equivalents at end of year	<u><u>4,566,197</u></u>	<u><u>1,053,486</u></u>
Cash and Cash equivalents consist of:		
Cash at bank and in hand	4,566,197	1,053,486
Cash and cash equivalents at 30 September 2022	<u><u>4,566,197</u></u>	<u><u>1,053,486</u></u>

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 30 SEPTEMBER 2023

	2023 £	2022 £
Reconciliation of profit to cash flow from operating activities		
Operating profit	2,599,267	1,614,111
Depreciation of tangible assets	860,006	838,717
(Profit)/Loss on tangible assets	-	(35,472)
(Profit)/Loss on intangible assets	-	-
(Increase)/decrease in stocks	(207,375)	(138,756)
(Increase)/decrease in debtors	640,069	41,319
(Decrease)/Increase in creditors within one year	197,436	(1,026,307)
Net cash flow from operating activities	<u>4,089,403</u>	<u>1,293,612</u>

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. The company has adopted FRS 102 in these financial statements.

1.1 Accounting convention and going concern

The financial statements are prepared under the historical cost convention

Going concern - The company's business activities, together with the factors likely to affect its future development and position, are set out in the Strategic Report on Page 1. The company is expected to generate positive cash flows for the foreseeable future. The company has a strong cash balance and is able to fund its operations through a combination of bank loans and profits. The company's forecasts and management figures indicate that it will be able to continue to operate within its existing facility. The Directors have a reasonable expectation that the company will be able to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

1.2 Compliance with accounting standards

The financial statements are prepared in accordance with applicable accounting UK Accounting Standards (UK GAAP), which have been applied consistently (except as otherwise stated).

1.3 Turnover

Turnover represents amounts receivable for goods and services net of VAT and trade discounts. The company recognises revenue when a) the significant risks and rewards of ownership have been transferred to the buyer; b) the amount of revenue can be measured reliably; c) it is probable that future economic benefits will flow to the entity; d) usually when the goods have been despatched from company premises.

1.4 Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:

i) Land & buildings include freehold and leasehold factories. Land and buildings are stated at cost less accumulated depreciation and accumulated impairment losses.

ii) Plant and machinery and fixtures and fittings are stated at cost less accumulated depreciation and accumulated impairment losses.

Land and buildings Freehold	2% on cost (buildings only)
Plant and machinery	10% on cost
Fixtures, fittings & equipment	20% on cost
Motor vehicles	25% on cost

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

1.5 Leasing and hire purchase commitments

Assets obtained under hire purchase contracts and finance leases are capitalised as tangible assets and depreciated over the shorter of the lease term and their useful lives. Obligations under such agreements are included in creditors net of the finance charge allocated to future periods. The finance element of the rental payment is charged to the profit and loss account so as to produce a constant periodic rate of charge on the net obligation outstanding in each period.

Rental payable under operating leases are charged against income on a straight line basis over the lease term.

1.6 Inventories

Stock is valued at the lower of cost and net realisable value. Cost is based on the first-in first-out principle. Finished Goods are valued using an average cost pricing method.

1.7 Pensions

The company operates a defined contribution scheme for the benefit of its employees. Contributions payable are charged to the profit and loss account in the year they are payable.

1.8 Taxation

Taxation expenses for the period comprises current and deferred tax recognised in the reporting period. Tax is recognised in the profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity respectively.

i) Current tax

Current tax is the amount of income tax payable in respect of the taxable profit for the year on prior years. Tax is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the period end.

Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

ii) Deferred tax

Deferred taxation is provided in full in respect of taxation deferred by timing differences between the treatment of certain items for taxation and accounting purposes. The deferred tax balance has not been discounted.

Deferred tax is recognised on all timing differences at the reporting date except for certain exceptions.

Unrelieved tax losses and other deferred tax assets are only recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

ASPAR PHARMACEUTICALS LIMITED

NOTE TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 SEPTEMBER 2023

1 Accounting policies

1.9 Foreign currency translation

i) Functional and presentation currency

The company's functional and presentational currency is the pound sterling.

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to profit and loss account.

ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the profit and loss account except where deferred in other comprehensive income as qualifying cash flow hedges.

1.10 Government grants

Grants are credited to deferred revenue. Grants towards capital expenditure are released to the profit and loss account over the expected useful life of the assets. Grants towards revenue expenditure are released to the profit and loss account as the related expenditure is incurred.

1.11 Financial instruments

Financial assets and impairment - financial assets comprise cash at bank and in hand, trade and other debtors; these are initially recorded at the cost on the date they originate and subsequently recorded at cost less provisions for impairment. The company considers evidence of impairment for all individual trade and other debtors, and any subsequent impairment is recognised in the profit and loss account. Impairment provisions are recognised when there is objective evidence that a financial asset or group of financial assets is impaired. Objective evidence includes significant financial difficulties of the counterparty, default or significant delays. Impairment provisions represent the differences between the net carrying amount of a financial asset and the value of the expected future cash receipts from that asset. Impairment provisions are recognised when there is objective evidence that a financial asset or group of financial assets is impaired. Objective evidence includes significant financial difficulties of the counterparty, default or significant delays in payment.

Financial liabilities - Financial liabilities comprise trade creditors, other creditors and accruals; these are initially recorded, and subsequently carried, at cost on the date they originate.

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

2 General Information

Aspar Pharmaceuticals Limited manufactures analgesics for the wholesale and retail trade from its plant in St. Albans and sells primarily within the UK.

3 Turnover

The total turnover of the company for the year has been derived from its principal activity wholly undertaken in the United Kingdom.

4 Operating profit	2023 £	2022 £
Operating profit is stated after charging:		
Depreciation of tangible assets	860,006	-
Loss on foreign exchange transactions	9,160	102,658
Auditor's remuneration	20,000	20,232
and after crediting:		
Profit on disposal of fixed assets	-	(35,472)

5 Investment income	2023 £	2022 £
Dividends received from subsidiary undertaking	-	778
	<u>-</u>	<u>778</u>
	<u>-</u>	<u>778</u>

6 Interest payable

On other loans wholly repayable within 5 years	-	54,164
	<u>-</u>	<u>54,164</u>
	<u>-</u>	<u>54,164</u>

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

7 Taxation	2023 £	2022 £
Domestic current year tax		
U.K. corporation tax	641,100	304,214
Adjustment for prior years	-	-
Total current tax	641,100	304,214
Deferred tax	(36,164)	(11,251)
	<u>604,936</u>	<u>292,963</u>
Factors affecting the tax charge for the year		
Profit on ordinary activities before taxation	<u>2,599,267</u>	<u>1,560,725</u>
Profit on ordinary activities before taxation multiplied by standard rate of UK corporation tax of 22%	<u>572,047</u>	<u>296,538</u>
Effects of:		
Depreciation add back	189,270	152,616
Capital allowances	(120,217)	(144,941)
Other tax adjustments	-	(11,250)
	<u>69,053</u>	<u>(3,575)</u>
Total tax charge for the year	<u><u>641,100</u></u>	<u><u>292,963</u></u>

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

8 Tangible fixed assets

	Land and Buildings £	Plant and Machinery £	Motor Vehicles £	Fixtures and fittings £	Total £
Cost or valuation					
As at 1 October 2022	6,915,286	12,741,241	131,123	1,794,354	21,582,004
Additions	-	259,979	-	12,500	272,479
Disposals	-	-	-	-	0
At 30 September 2023	<u>6,915,286</u>	<u>13,001,220</u>	<u>131,123</u>	<u>1,806,854</u>	<u>21,854,483</u>
Provision for depreciation and impairment					
As at 1 October 2022	830,770	9,987,854	32,583	1,708,703	12,559,910
Charge for the year	118,610	687,512	20,709	33,175	860,006
Disposals	-	-	-	-	-
At 30 September 2023	<u>949,380</u>	<u>10,675,366</u>	<u>53,292</u>	<u>1,741,878</u>	<u>13,419,916</u>
Net book value					
At 30 September 2023	<u>5,965,906</u>	<u>2,325,854</u>	<u>77,831</u>	<u>64,976</u>	<u>8,434,567</u>
At 30 September 2022	<u>6,084,516</u>	<u>2,753,387</u>	<u>98,540</u>	<u>85,651</u>	<u>9,022,094</u>

The property is subject to a fixed and floating charge from Barclays Bank dated 28 July 2016.

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

9 Stocks	2023	2022
	£	£
Raw materials	1,179,732	1,042,143
Work in Progress	122,871	139,408
Finished goods and goods for resale	1,792,777	1,706,454
	<hr/>	<hr/>
	3,095,380	2,888,005
	<hr/>	<hr/>
 10 Debtors	 2023	 2022
	£	£
Trade debtors	2,133,973	2,814,964
Prepayments and accrued income	174,476	133,909
Other debtors	1,875	1,520
	<hr/>	<hr/>
	2,310,324	2,950,393
	<hr/>	<hr/>
 11 Creditors: amounts falling due within one year	 2023	 2022
	£	£
Trade creditors	980,372	682,176
Corporation tax	641,100	304,214
Other taxes and social security costs	357,208	403,671
Accruals and deferred income	275,367	129,664
Directors' current account	-	200,000
	<hr/>	<hr/>
	2,254,047	1,719,725
	<hr/>	<hr/>

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

12 Provisions for liabilities

Deferred Tax Liability £

Balance at 1 October 2022
Profit and loss account

5,861
(36,164)

(30,303)

The deferred tax liability is made up as follows:

2023
£

2022
£

Accelerated capital allowances

(30,303)

-

13 Pension and other post-retirement benefit commitments

2023
£

2022
£

Defined contribution

Contributions payable by the company for the year

49,795

51,017

14 Share capital

2023
£

2022
£

Allotted, called up and fully paid

45,100 Ordinary Shares of £1 each

45,100

45,100

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

15 Transactions with Directors

As at 30 September 2023 the company had repaid T.E. Prudhoe £200,000.
The loan has been fully repaid.

16 Directors' remuneration	2023 £	2022 £
Remuneration for qualifying services	283,751	285,377
	<u>283,751</u>	<u>285,377</u>

Remuneration disclosed above include the following amounts paid to the highest paid director:

Remuneration for qualifying services	153,750	153,750
	<u>153,750</u>	<u>153,750</u>

ASPAR PHARMACEUTICALS LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2023

17 Number of employees

The average number of employees (including directors) during the year was:

	2023 Number	2022 Number
Production	61	62
Distribution	7	7
Office	1	1
Management	3	3
	<hr/> 72	<hr/> 73

Employment costs

	2023 £	2022 £
Wages and salaries	2,748,682	2,790,500
Social security costs	289,563	288,415
Other pension costs	49,795	51,017
	<hr/> 3,088,040	<hr/> 3,129,932

18 Subsequent Events

On 27 October 2023 the company purchased additional freehold property at 13 & 14 Alban Park, Hatfield, St Albans, AL4 0JJ for the sum of £1,622,000.

19 Control

The ultimate controlling party is T.E. Prudhoe